<DOC>
	<DOCNO>NCT00951132</DOCNO>
	<brief_summary>The purpose study investigate whether rosuvastatin decrease measure inflammation depressive patient .</brief_summary>
	<brief_title>Depression Cardiovascular Risk Markers : Effects Rosuvastatin Therapy</brief_title>
	<detailed_description>Depression associate increase risk cardiovascular disease , one possible mechanism systemic inflammation . Further , patient high risk cardiovascular disease , rosuvastatin decrease risk , especially among patient increase inflammation . This proof-of-concept study investigate whether antiinflammatory effect rosuvastatin similar depressive patient cardiovascular disease .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Persisting selfreported depressive symptom &gt; 5 week Indications aortic atherosclerosis PET/CT Clinical indication statin use . Contraindication statin , PET/CT MRI . Established cardiovascular disease . Bipolar disorder og comorbid psychosis .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
</DOC>